Bio-Rad Laboratories/$BIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Ticker
$BIO
Sector
Primary listing
NYSE
Employees
7,700
Headquarters
Website
BIO Metrics
BasicAdvanced
$7.5B
24.88
$11.49
0.95
-
Price and volume
Market cap
$7.5B
Beta
0.95
52-week high
$373.69
52-week low
$211.43
Average daily volume
274K
Financial strength
Current ratio
5.121
Quick ratio
3.374
Long term debt to equity
19.161
Total debt to equity
19.73
Interest coverage (TTM)
5.17%
Profitability
EBITDA (TTM)
410.3
Gross margin (TTM)
52.96%
Net profit margin (TTM)
12.50%
Operating margin (TTM)
9.92%
Effective tax rate (TTM)
29.08%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
1.59%
Return on equity (TTM)
4.59%
Valuation
Price to earnings (TTM)
24.878
Price to revenue (TTM)
3.109
Price to book
1.06
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
22.846
Free cash flow yield (TTM)
4.38%
Free cash flow per share (TTM)
12.514
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
-124.88%
3-year revenue growth (CAGR)
-3.82%
10-year revenue growth (CAGR)
1.94%
3-year earnings per share growth (CAGR)
-43.76%
10-year earnings per share growth (CAGR)
13.26%
What the Analysts think about BIO
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
Bulls say / Bears say
The completion of the Stilla Technologies acquisition expands Bio-Rad’s Droplet Digital PCR portfolio with the QX Continuum™ and QX700™ platforms, strengthening its leadership position in the rapidly growing dPCR market, which is projected to grow at a 23.1% CAGR through 2032. (Nasdaq)
In Q2 2025, Bio-Rad surpassed analyst expectations with non-GAAP revenue of $651.6 million (up 2.1% YoY) and EPS of $2.61, reflecting steady demand in its core markets. (Investing.com)
The company raised its full-year 2025 outlook, now forecasting non-GAAP, currency-neutral revenue growth of 0–1.0% and operating margins of 12.0–13.0%, up from the previous guidance of –1.0–1.5% growth and 10.0–12.0% margins. (Investing.com)
Clinical Diagnostics segment net sales were flat at $388.8 million in Q2 2025 and declined 0.7% on a currency-neutral basis due to lower diabetes testing reimbursements in China. (Business Wire)
GAAP gross margin fell to 53.0% in Q2 2025 from 55.6% last year, pressured by higher tariffs and an unfavorable product mix. (Business Wire)
First-quarter 2025 revenues decreased 4.2% YoY to $585.4 million, with Life Science segment sales down 5.4% due to continued weakness in the academic research markets, indicating persistent challenges. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BIO Financial Performance
Revenues and expenses
BIO Earnings Performance
Company profitability
BIO News
AllArticlesVideos
Bio-Rad's Management to Participate in Upcoming Investor Conferences
Business Wire3 weeks ago
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
Benzinga2 months ago
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Rad Laboratories stock?
Bio-Rad Laboratories (BIO) has a market cap of $7.5B as of September 16, 2025.
What is the P/E ratio for Bio-Rad Laboratories stock?
The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 24.88 as of September 16, 2025.
Does Bio-Rad Laboratories stock pay dividends?
No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Bio-Rad Laboratories dividend payment date?
Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.